肝转移是否是接受免疫检查点抑制剂（ICIs）的转移性非小细胞肺癌（NSCLC）患者生存预后因素尚未确定。我们比较了NSCLC患者在有或没有肝转移情况下接受ICIs的疗效，旨在评估肝转移对NSCLC生存的影响。我们在Pubmed、Embase和Cochrane库数据库中系统地搜索了有关ICIs疗效的随机对照试验（RCT）的文献，时间跨度为2000年1月1日至2022年6月1日。审查员筛选文献、提取数据并进行质量评估，并使用RevMan 5.4软件和Stata 14进行分析。共纳入了17个RCT，发表时间为2019年至2022年。对于有肝转移的NSCLC患者，接受ICIs治疗后疾病进展的风险降低了36%（HR = 0.64；95% CI：0.55-0.75；P＜0.01），死亡风险（HR = 0.82；95% CI：0.72-0.94；P＜0.01）也有所降低。对于没有肝转移的患者，与对照组相比，PFS（HR = 0.56；95% CI：0.52-0.60；P＜0.01）和OS（HR = 0.73；95% CI：0.67-0.80；P＜0.01）都有显着改善。对于肝转移患者的OS的亚组分析表明，OS的收益与治疗策略有关（抗-PD-L1加化疗与单纯化疗相比，HR = 1.04；95% CI：0.81-1.34；P = 0.75）。对于有或没有肝转移的NSCLC患者，ICIs治疗均能改善PFS和OS，特别是对于没有肝转移的患者。需要更多的RCT来验证这些发现。

It is not well determined whether liver metastasis is a prognostic factor for survival of metastatic non-small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitors (ICIs). We compared the efficacy of ICIs in patients with NSCLC with or without liver metastases, aiming to evaluate the impact of liver metastasis on survival of NSCLC.We systematically searched Pubmed, Embase, and the Cochrane library databases for randomized controlled trials (RCTs) on the efficacy of ICIs in the treatment of NSCLC patients with or without liver metastases. The duration of this search was from January 1, 2000 to June 1, 2022. The reviewers screened the literature, extracted data and conducted quality assessment, and used RevMan 5.4 software and Stata 14 to perform analyses.A total of 17 RCTs were included, published from 2019 to 2022. For NSCLC patients with liver metastases, the risk of disease progression decreased by 36% (HR = 0.64; 95% CI: 0.55-0.75; P < .01) when treated with ICIs, and the death risk (HR = 0.82; 95% CI: 0.72-0.94; P < .01) was also reduced after ICIs treatment. For those without liver metastases, they had significantly improved PFS (HR = 0.56; 95% CI: 0.52-0.60; P < .01) and OS (HR = 0.73; 95% CI: 0.67-0.80; P < .01), compared to those of the control group. Subgroup analysis of OS in liver metastases patients suggested that OS benefit was associated with treatment strategy (for anti-PD-L1 plus chemotherapy versus chemotherapy, HR=1.04; 95% CI: 0.81-1.34; P =.75).For NSCLC patients with or without liver metastases, ICIs administration could improve both PFS and OS, especially for those without liver metastases. More RCTs are essential to verify these findings.